DS-2243 / Daiichi Sankyo - LARVOL DELTA

A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT06644755 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1 data • Oncology • Solid Tumor • HLA-A

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer